Ask AI
ProCE Banner Activity

Maximizing Benefit With the Expanding Options for Gastric Cancer: Expert Answers to Frequently Asked Questions

Clinical Thought

In this commentary, an expert faculty addresses questions on the use of contemporary therapeutic regimens for patients with gastric cancer. 

Released: December 22, 2023

Continue Activity View Activity

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme, LLC.

Merck Sharp & Dohme, LLC

Faculty Disclosure

Primary Author

James M. Cleary, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

James M. Cleary, MD, PhD: consultant/advisor/speaker: Abdera, BeOne, Gilead, Prelude; researcher: Amgen, Arcus, BMS, GlaxoSmithKline, Merck, Merus, Pyxis, Servier; data and safety monitoring committee: AstraZeneca.